| Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. | |
| | |
MedLine Citation:
|
PMID: 21438812 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atherogenic dyslipidemia, including low HDL levels, is the major contributor of residual risk of cardiovascular disease that remains even after aggressive statin therapy to reduce LDL-cholesterol. Currently, distinction is not made between HDL-cholesterol and HDL, which is a lipoprotein consisting of several proteins and a core containing cholesteryl esters (CEs). The importance of assessing HDL functionality, specifically its role in facilitating cholesterol efflux from foam cells, is relevant to atherogenesis. Since HDLs can only remove unesterified cholesterol from macrophages while cholesterol is stored as CEs within foam cells, intracellular CE hydrolysis by CE hydrolase is vital. Reduction in macrophage lipid burden not only attenuates atherosclerosis but also reduces inflammation and linked pathologies such as Type 2 diabetes and chronic kidney disease. Targeting reduction in macrophage CE levels and focusing on enhancing cholesterol flux from peripheral tissues to liver for final elimination is proposed. |
| | |
Authors:
|
Shobha Ghosh |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 9 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-28 Completed Date: 2011-07-26 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 329-40 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Division of Pulmonary and Critical Care, VCU Medical Center, Richmond, VA 23298-0050, USA. shobha@vcu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Atherosclerosis / metabolism, physiopathology Cholesterol / metabolism* Cholesterol Esters / metabolism* Homeostasis Humans Inflammation / physiopathology Lipid Mobilization Lipoproteins, HDL / metabolism Macrophages / metabolism Metabolic Diseases / physiopathology* |
| Grant Support | |
ID/Acronym/Agency:
|
HL069946/HL/NHLBI NIH HHS; HL097346/HL/NHLBI NIH HHS; R01 HL069946-09/HL/NHLBI NIH HHS; R01 HL097346-03/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol Esters; 0/Lipoproteins, HDL; 57-88-5/Cholesterol |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.
Next Document: Diabetic dyslipidemia or 'diabetes lipidus'?